New Clinical Research Hub Launched by Thermo Fisher in Wisconsin

Thermo Fisher Scientific Inc.'s PPD clinical research division has opened a new 72,500-square-foot clinical research laboratory at its GMP facility in Middleton, Wisconsin. This expansion enhances the site's CMC analytical capabilities, supporting its clinical development and laboratory services aimed at advancing health by assisting clients in bringing transformative medications to market.

Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific, said in a statement, “As research in bio-pharmaceutical therapies continues to rapidly expand, we are excited to expand our overall capacity and capabilities in laboratory services to help our customers deliver therapies that meet the highest quality and safety standards for patients. This $58 million investment to expand the site is a testament to our dedication in supporting Thermo Fisher’s Mission of making the world healthier, cleaner and safer.”

The GMP facility provides analytical services for small molecules and biologics, including biopharmaceuticals, inhaled pharmaceuticals, and device testing, as well as cell and gene therapy, protein characterization, and mass spectrometry analysis throughout all stages of drug development.

The recent expansion at the GMP campus includes a versatile biosafety level 2 laboratory, specially designed spaces for liquid chromatography-mass spectrometry and protein characterization, two extensive molecular suites with controlled access pre- and post-amplification labs, and two large general-purpose labs. This addition will bring up to 350 scientists and laboratory support staff, complementing the nearly 2,300 employees already at the research campus.